Abstract
Platelet function testing was introduced more than a century ago with the invention of bleeding time; a test which has now been replaced by more accurate methods. Light transmittance aggregometry is traditionally regarded as the gold standard for evaluating platelet function. However, lately the position of light transmittance aggregometry has been challenged by a panel of new instruments.
Aspirin and P2Y12-inhibitors are antiplatelet drugs used for secondary prevention of cardiovascular disease. However, an increasing recognition of the fact that not all patients respond adequately to these agents has prompted a focus on individualising antiplatelet treatment. Platelet function testing enables the detection of patients with high on-treatment platelet reactivity and facilitates individually tailored antiplatelet therapy, yet platelet function tests have still not been adopted into routine clinical practice. The present review outlines key milestones of the development of platelet function testing and provides an up-to-date overview of currently available tests and important studies evaluating their strengths and limitations in a clinical context.Keywords: Acute coronary syndrome, antiplatelet agents, aspirin, clopidogrel, coronary artery disease, individualized medicine, platelet function tests, platelets
Current Pharmaceutical Design
Title:Platelet Function Testing in Atherothrombotic Disease
Volume: 18 Issue: 33
Author(s): Erik Lerkevang Grove, Robert F. Storey and Morten Wurtz
Affiliation:
Keywords: Acute coronary syndrome, antiplatelet agents, aspirin, clopidogrel, coronary artery disease, individualized medicine, platelet function tests, platelets
Abstract: Platelet function testing was introduced more than a century ago with the invention of bleeding time; a test which has now been replaced by more accurate methods. Light transmittance aggregometry is traditionally regarded as the gold standard for evaluating platelet function. However, lately the position of light transmittance aggregometry has been challenged by a panel of new instruments.
Aspirin and P2Y12-inhibitors are antiplatelet drugs used for secondary prevention of cardiovascular disease. However, an increasing recognition of the fact that not all patients respond adequately to these agents has prompted a focus on individualising antiplatelet treatment. Platelet function testing enables the detection of patients with high on-treatment platelet reactivity and facilitates individually tailored antiplatelet therapy, yet platelet function tests have still not been adopted into routine clinical practice. The present review outlines key milestones of the development of platelet function testing and provides an up-to-date overview of currently available tests and important studies evaluating their strengths and limitations in a clinical context.Export Options
About this article
Cite this article as:
Lerkevang Grove Erik, F. Storey Robert and Wurtz Morten, Platelet Function Testing in Atherothrombotic Disease, Current Pharmaceutical Design 2012; 18 (33) . https://dx.doi.org/10.2174/138161212803251862
DOI https://dx.doi.org/10.2174/138161212803251862 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Effect of Non-Ionizing Electromagnetic Fields of Anthropic Origin on Male Fertility
Current Chemical Biology Analysis of Contrast-Enhanced Intravascular Ultrasound Images for the Assessment of Coronary Plaque Neoangiogenesis: Another Step Closer to the Identification of the Vulnerable Plaque
Current Pharmaceutical Design New Thrombin and Factor Xa Inhibitors for Primary and Secondary Prevention of Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Tumor Necrosis Factor-α and C-C Motif Chemokine Ligand 18 Associate with Atherosclerotic Lipid Accumulation In situ and In vitro
Current Pharmaceutical Design The Role of the Chemokines in Myocardial Ischemia and Reperfusion
Current Vascular Pharmacology Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Isolation and Characterization of CD39-like Phosphodiesterase (Cc-PDE) from <i>Cerastes cerastes</i> Venom: Molecular Inhibitory Mechanism of Antiaggregation and Anticoagulation
Protein & Peptide Letters Collagen Cross-link Breakers:A Beginning of a New Era in the Treatment of Cardiovascular Changes Associated with Aging,Diabetes,and Hypertension
Current Drug Targets - Cardiovascular & Hematological Disorders Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design Technetium-99m Cysteine; A Novel Radiopharmaceutical for Detection of Experimental Myocardial Infarction in Rats
Current Radiopharmaceuticals Synthesis of 1,2,4-triazole Derivatives: Binding Properties on Endothelin Receptors
Medicinal Chemistry New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia
Current Medicinal Chemistry Effect of GLP-1 Based Therapies on Diabetic Dyslipidemia
Current Diabetes Reviews Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design New Physiological Targets Within the Kidney for Antihypertensive Therapy
Drug Design Reviews - Online (Discontinued) Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets